INT199570

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2006
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 4.41
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
liver 1
Tks (Mus musculus)
Pain Link Frequency Relevance Heat
adenocard 5 94.80 High High
cytokine 31 85.36 High High
Pain 25 78.48 Quite High
tricyclic antidepressant 13 78.08 Quite High
antidepressant 43 77.04 Quite High
Lasting pain 13 72.64 Quite High
Inflammation 36 66.16 Quite High
rheumatoid arthritis 65 61.80 Quite High
sSRI 30 59.44 Quite High
sNRI 10 55.44 Quite High
Disease Link Frequency Relevance Heat
Anxiety Disorder 22 100.00 Very High Very High Very High
Phobia 6 100.00 Very High Very High Very High
Vomiting 13 96.32 Very High Very High Very High
Toxicity 95 95.20 Very High Very High Very High
Recurrence 25 94.12 High High
Renal Cell Carcinoma 250 92.88 High High
Disease 186 92.60 High High
Cancer 149 91.72 High High
Melanoma 15 80.24 Quite High
Pain 36 78.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Semaxinib (SU5416), an inhibitor of the VEGFR1 and VEGFR2 TKs, has also been studied in combination with INF-?
Negative_regulation (inhibitor) of TKs
1) Confidence 0.26 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.73 Pain Relevance 0
Concomitantly, a number of TKs have been implicated in the negative regulation of TLR signalling.
Negative_regulation (number) of TKs
2) Confidence 0.21 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592774 Disease Relevance 0.18 Pain Relevance 0.13
Sorafenib (Nexavar, BAY 43-9006) is a small molecule drug that, among other targets, inhibits tyrosine kinases (TKs), enzymes that catalyze the transfer of ?
Negative_regulation (inhibits) of TKs
3) Confidence 0.19 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.65 Pain Relevance 0.05
The IC50 values for the receptor TKs EGFR and HER-2 were greater than 10 000 nmol/L.
Negative_regulation (receptor) of TKs
4) Confidence 0.19 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.12 Pain Relevance 0
Sorafenib inhibits multiple targets including the BRAF, V600E BRAF, and CRAF non-receptor TKs and the VEGF, PDGF, and c-KIT receptor TKs.
Negative_regulation (inhibits) of TKs
5) Confidence 0.17 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 1.05 Pain Relevance 0
In addition to inhibition of Raf family non-receptor kinases, sorafenib also inhibits a number of receptor TKs in cell-free assays known to be involved in angiogenesis and tumorigenesis such as VEGFR2, VEGFR3, fetal liver tyrosine kinase 3 (Flt-3), c-KIT, and PDGFR.
Negative_regulation (number) of TKs in liver
6) Confidence 0.17 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.53 Pain Relevance 0
TKS offensive anxiety (fear of offending other people), which was assessed by an original scale developed by the authors, was significantly reduced.
Negative_regulation (reduced) of TKS associated with phobia and anxiety disorder
7) Confidence 0.05 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654524 Disease Relevance 1.15 Pain Relevance 0.41

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox